Asherman syndrome in adenomyosis treated with uterine artery embolization: incidence predictive factors
This retrospective study of 195 adenomyosis patients found a 12.82% incidence of Asherman syndrome after uterine artery embolization, with low vascularity identified as a significant risk factor.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
This retrospective study evaluated 195 women with adenomyosis who underwent uterine artery embolization between 2009 and 2016, recording preoperative and intraoperative potential risk factors and monitoring for Asherman syndrome over 0–15 months. The incidence of Asherman syndrome events after UAE was 12.82% (25/195). Univariate and multivariate logistic regression identified low vascularity of the adenomyosis at the time of UAE as significantly associated with increased AS risk (P = 0.019). The authors’ limitation is that the analysis was retrospective, based on recorded risk factors, with follow-up limited to the stated monitoring window. This paper is centrally about adenomyosis — it analyzes incidence predictive factors for Asherman syndrome after uterine artery embolization, focusing specifically on lesion vascularity in adenomyosis.
Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works
Abstract
Full text
9,470 characters
· extracted from
oa-doi-fallback
· 5 sections
· click to expand
Abstract
Materials and methods
Results
Conclusion
References
Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.
My notes (saved in your browser only)
Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works
Condition tags
MeSH descriptors
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (44)
- Can measurement of apparent diffusion coefficient before treatment predict the response to uterine artery embolization for adenomyosis? via openalex
- Is it time for a paradigm shift in drug research and development in endometriosis/adenomyosis? via openalex
- Long-Term Follow-up of Uterine Artery Embolization for Symptomatic Adenomyosis via openalex
- Long-Term Results of Uterine Artery Embolization for Symptomatic Adenomyosis via openalex
- Management of uterine adenomyosis: current trends and uterine artery embolization as a potential alternative to hysterectomy via openalex
- MRI of Adenomyosis: Changes with Uterine Artery Embolization via openalex
- Outcomes in Adenomyosis Treated with Uterine Artery Embolization Are Associated with Lesion Vascularity: A Long-Term Follow-Up Study of 252 Cases via openalex
- Pathological findings of uterine leiomyomas and adenomyosis following uterine artery embolization via openalex
- Prediction of early response to uterine arterial embolisation of adenomyosis: value of T2 signal intensity ratio of adenomyosis via openalex
- Uterine artery embolisation for symptomatic adenomyosis—Mid-term results via openalex
- Uterine artery embolisation in women with symptomatic adenomyosis via openalex
- Uterine Artery Embolization for Symptomatic Adenomyosis: 7-Year Clinical Follow-up Using UFS-Qol Questionnaire via openalex
- Uterine Artery Embolization for the Treatment of Adenomyosis: A Systematic Review and Meta-Analysis via openalex
- W2038950921 via openalex
- W2037478149 via openalex
- W2047107423 via openalex
- W2048036760 via openalex
- W2021350721 via openalex
- W2053711852 via openalex
- W2061212434 via openalex
- W2071061973 via openalex
- W2073157306 via openalex
- W2007017189 via openalex
- W2081884551 via openalex
- W2083884788 via openalex
- W2103802992 via openalex
- W2108676997 via openalex
- W2121306814 via openalex
- W2121398000 via openalex
- W2147763751 via openalex
- W2162037593 via openalex
- W2298291530 via openalex
- W2532973999 via openalex
- W2000481045 via openalex
- W2604435318 via openalex
- W1973005384 via openalex
- W2749164399 via openalex
- W2755027851 via openalex
- W1495928164 via openalex
- W1881066505 via openalex
- W2897457508 via openalex
- W1561621573 via openalex
- W1542775365 via openalex
- W3035963869 via openalex
Cited by (5)
- Uterine artery embolization for the treatment of symptomatic adenomyosis: a systematic review 2026
- Factors associated with dysmenorrhoea and menorrhagia improvement in patients with adenomyosis after uterine artery embolisation 2024
- Uterine Artery Embolization for Adenomyosis: A Review of Imaging, Techniques, Complications and Outcomes 2023
- Clinical Efficacy and Safety of Fertility-Preservative PUSH Surgery for Diffuse Adenomyosis: Evidence from a 11-Year Prospective Investigation 2021
- The Advantages and Disadvantages of Uterine Artery Embolization in Women with Adenomyosis: What’s New? 2021
Source provenance
- europepmc
- last seen: 2026-08-22T06:09:51.966504+00:00
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- pubmed
- last seen: 2026-05-13T22:22:17.025735+00:00